IVIG

Intravenous immunoglobulin (IVIG) has proven efficacy in autoimmune neuropathies, with mixed but promising outcomes in severe COVID-19 cases and post-acute sequelae of SARS-CoV-2 infection trials.

No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.

IVIG was found to cease development of new lesions and heal previously documented erosions without adverse events to the patient or fetus.

Efforts include a mandatory intravenous immunoglobulin ordering form, blood bank gatekeeping, and a stewardship committee to ensure optimized use.

Intravenous immunoglobulin prescriptions deemed non-compliant according to French national guidelines were more common in younger patients.

Utilizing data from the CHAMPION MG trial, investigators found that many patients had responded to ravulizumab and returned to daily activities within 2 weeks.

Therapy-related complications, in addition to financial obstacles, can complicate myasthenia gravis treatment.

Recognizing repeat dosing efforts is important to improving outcomes in patients with Guillain-Barré syndrome who do not respond to IVIG.

Glucocorticoids improved outcomes for patients with Kawasaki disease at high risk of IVIG resistance without glucocorticoid-related adverse effects.

Though both treatments come with positives and negatives, ultimately, individual patient clinical presentation and accessibility will determine the proper treatment for myasthenic crisis.

By utilizing a lower dose, patients can avoid potential adverse events and high financial burden.

Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.

In a patient with long-shedding SARS-CoV-2, transfusion-related acute lung injury developed after intravenous immunoglobulin, emphasizing careful treatment considerations.

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.

Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.

Myasthenia gravis is a chronic autoimmune disease that causes muscle weakness and fatigue, with 4 main treatment options available.

For those with unexplained pregnancy loss, these results could prove promising improvements to birth outcomes.

The use of intravenous immunoglobulin led to positive protective effects on osteoporosis.

Noticing indicators of IVIG non-responsiveness can lead to better outcomes among patients with Kawasaki disease as treatment is adjusted.

Investigators analyzed a series of disease-modifying therapies in a multi-decade trial.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

The systematic review summarized all available evidence on the subject, finding that intravenous immunoglobulin could have a role in treatment.

Intravenous Immunoglobulin as a therapy for patients with pyoderma gangrenosum could open new treatment avenues for the rare and challenging condition.

Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.

In an analysis of 16 immunocompromised patients with COVID-19, intravenous immunoglobulin was effective and associated with clinical cure.

The presence of glutamic acid decarboxylase antibodies in intravenous immunoglobulin can lead to a misdiagnosis of type 1 diabetes mellitus if a false-positive result is garnered.

By functioning as an antibody replacement therapy, IVIG can be used to manage a wide range of inflammatory and autoimmune disorders.

A lack of widespread hepatitis B screenings compound with the issue of inaccurate test results, which can complicate treatment with intravenous immunoglobulin.

It is essential for clinicians to properly diagnose patients with suspected AVWS and provide them proper treatment, which could be intravenous immunoglobulin.